Fri. 26 Apr 2024, 8:35am ET
Benzinga
News, Contracts
- $15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
- ALLO-316 Illustrates Proof-of-Concept in RCC and the Potential of Dagger® Technology to Optimize CAR T Cell Expansion and Persistence